DRÄGER’S EXECUTION IS ON POINT (BUY, 38% UPSIDE)
29/09/25 -" At the start of summer 2024, our optimism on Drägerwerk (BUY; Germany) was underpinned by its irrefutable product quality, supported by a strong R&D programme, and a management committed to ..."
Pages
48
Language
English
Published on
29/09/25
You may also be interested by these reports :
30/09/25
We have trimmed our estimates and target price to reflect the still persistent weakness in the Equipment business. However, with nearly 80% of ...
30/09/25
Despite the hit to our near-term earnings estimates, our intrinsic valuations are relatively buffered by our belief that the underlying structural ...
29/09/25
At the start of summer 2024, our optimism on Drägerwerk (BUY; Germany) was underpinned by its irrefutable product quality, supported by a strong R&D ...
25/09/25
We have revised our target price downward, as outlined in the EPS section, and removed the 20% valuation premium from the peer-based valuation due to ...